CA-RESOLVE-SYSTEMS
Cherwell Software LLC, a leading provider of IT Service Management (ITSM) and Enterprise Service Management (ESM) solutions, joins forces with Resolve Systems , a leader in enterprise automation and AIOps, to help companies better manage their complex IT environments through workflow automation and auto-discovery and dependency mapping. Cherwell is now an official reseller of Resolve products and can seamlessly deliver the integrated offering to their customers. Cherwell selected Resolve’s automated discovery and dependency mapping solution based on its robust capabilities and customer success.
The collaboration between Resolve and Cherwell provides a complete solution for streamlining IT operations and accelerating service delivery. Combining best-in-class ITSM and robust discovery and dependency mapping immediately provides customers deep visibility into complex, hybrid environments, while also forging a strong foundation to advance AIOps initiatives.
“By partnering with one of the leaders in enterprise service management and ITSM, we’re able to offer a comprehensive solution to automating IT operations and accelerating service desk transformation,” said Rob Kelsall, VP of Global Sales Engineering for Resolve. “We look forward to helping Cherwell customers achieve agile, autonomous operations, starting with automated discovery and dynamic dependency mapping.”
“As a fellow leader in the domain, we couldn’t be more pleased that Resolve is expanding their collaboration with us. Together, our goal is to offer exceptional, end-to-end solutions for the entire enterprise,” said Scott Gainey, chief marketing officer of Cherwell.
By combining Resolve’s discovery and dependency mapping solution with Cherwell ITSM, customers can:
- Eliminate manual work by automating discovery and real-time updates to their Cherwell CMDB
- Identify and track dynamic, multi-layer relationships between applications and hybrid infrastructure
- Auto-generate complex topology maps to visualize infrastructure relationships and facilitate troubleshooting
Resolve integrates seamlessly with Cherwell’s flagship offering, Cherwell Service Management — delivered on Cherwell's powerful and flexible no-code CORE™ platform. Cherwell enables IT, HR, Facilities, and other teams to implement, automate and modernize service and support processes to meet new and evolving needs — at a fraction of the cost and complexity of other tools.
Resolve’s discovery and dependency mapping product is part of their comprehensive automation and AIOps platform, which is integrated with Cherwell’s IT Service Management® solution. Resolve provides full-stack visibility into complex, hybrid IT environments by performing agentless auto-discovery of all physical and virtual entities, mapping dependencies, and creating topology maps that enable IT teams to see what they are managing. This integration can be found on the Cherwell Marketplace .
To learn more about Cherwell’s new discovery and dependency mapping, powered by Resolve, visit cherwell.com/products/it-service-management/discovery-and-dependency-mapping/ .
About Cherwell
Cherwell (@Cherwell) empowers organizations to transform their business through the rapid adoption and easy management of digital services. Cherwell’s adaptable platform has enabled thousands of organizations to modernize their business operations with customizable service management, automation, and reporting across the enterprise. For more information, visit: https://www.cherwell.com .
About Resolve Systems
Resolve helps IT teams achieve agile, autonomous operations with an industry-leading, enterprise automation and AIOps platform. By combining insights from artificial intelligence with powerful, cross-domain automation, Resolve handles a wide array of IT operations – from dependency mapping, event correlation, and predictive analytics to intelligently automating actions based on those findings. Purpose-built to address challenges posed by increasing IT complexity, Resolve enables organizations to maximize operational efficiency, reduce costs, quickly troubleshoot and fix problems, and accelerate service delivery. See why the Fortune 1000, leading MSPs, and the largest communication service providers on the planet trust Resolve to power millions of automations every day. Learn more at resolve.io or follow us on Twitter @ResolveSystems .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005210/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom